Autologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Impact of Age

Publication date: Available online 25 November 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Binod Dhakal, Ariel Nelson, Guru Subramanian Guru Murthy, Raphael Fraser, Daniel Eastwood, Mehdi Hamadani, Marcello Pasquini, Anita D’Souza, Parameswaran Hari In both the novel and pre-novel agent era, high dose therapy followed by autologous hematopoietic cell transplant (AHCT) has been shown to prolong survival in multiple myeloma (MM) in randomized trials, but only included patients 65 years and younger. Given the median age at diagnosis is 66 years, it is important to know the outcomes of AHCT in older patients. Similarly, the definite outcomes of AHCT in very young patients (<50 years) is also lacking as they represent a very small proportion in clinical trials. We analyzed a consecutive cohort of patients with MM receiving AHCT from 2000-2015 in two different age groups, old (>70 years) and young (≤50 years) and compared the outcomes. The primary objectives were to assess overall survival (OS), progression free survival, (PFS), and non-relapse mortality (NRM) in these two groups. Eighty-six patients were young (≤50 years), while 105 patients were old (>70 years). Young patients had better performance status and lower co-morbidity index, while majority of old patients received melphalan dose between 140-180 mg/m2. Median follow up in the young was 33 months (range, 2-164) compared to the 22.5 months (3-133) in the old group (p...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research